Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma

Pediatr Blood Cancer. 2010 Dec 1;55(6):1217-20. doi: 10.1002/pbc.22611.

Abstract

Renal medullary carcinoma (RMC) is a rare and aggressive malignancy seen primarily in patients with sickle-cell trait. We report a complete response to carboplatin, paclitaxel, and gemcitabine in a patient with advanced metastatic RMC.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary*
  • Child
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Gemcitabine
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / secondary*
  • Male
  • Paclitaxel / administration & dosage
  • Sickle Cell Trait / drug therapy*
  • Sickle Cell Trait / pathology*
  • Treatment Outcome

Substances

  • Deoxycytidine
  • Carboplatin
  • Paclitaxel
  • Gemcitabine